Idiopathic Pulmonary Fibrosis (IPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Idiopathic Pulmonary Fibrosis (IPF) is a chronic condition characterized by lung scar tissue, developing gradually over several years and without any known cause. The primary symptoms associated with IPF are exercise-induced shortness of breath and a persistent, dry cough. IPF falls under interstitial lung disease (ILD), more accurately referred to as diffuse parenchymal lung disease (DPLD). Within this broad classification of lung disorders, IPF belongs explicitly to a subgroup known as idiopathic interstitial pneumonia (IIP). The typical age of presentation for IPF is around 66 years. Initial symptoms often include exertional breathlessness and persistent dry cough. When examining the lungs of IPF patients, healthcare providers frequently detect early inspiratory crackling sounds, mainly in the lower posterior lung regions. Approximately 50% of IPF patients may also exhibit clubbing of the fingers. Over time, exertional dyspnea worsens progressively, spanning months to years. IPF can be identified through high-resolution computed tomography, which reveals peripheral subpleural reticular opacities in the lower lung lobes, often accompanied by subpleural honeycomb changes. Differential diagnosis involves distinguishing IPF from other idiopathic interstitial pneumonias, connective tissue diseases such as systemic sclerosis, polymyositis, and rheumatoid arthritis, as well as various forms of autoimmune disorders and chronic hypersensitivity pneumonitis. Environmental and sometimes occupational exposures are also taken into consideration. Current international guidelines recommend two medications, pirfenidone and nintedanib, for treating IPF. These medications are known to slow down the progression of the disease, as evidenced by a roughly 50% reduction in the decline of forced vital capacity. They are considered safe and effective.
·
IPF affects approximately 132,000 individuals
in the United States, with around 50,000 new diagnoses made each year.
Thelansis’s
“Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Idiopathic
Pulmonary Fibrosis (IPF) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Idiopathic Pulmonary
Fibrosis (IPF) across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Idiopathic
Pulmonary Fibrosis (IPF) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment